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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

IS THE CUSTOMER ALWAYS RIGHT? DEPARTMENT OF HEALTH
AND HUMAN SERVICES’ PROPOSED REGULATIONS ALLOW
INSTITUTIONAL REVIEW BOARDS TO PLACE CUSTOMER
SERVICE AHEAD OF THE WELFARE OF RESEARCH
PARTICIPANTS

INTRODUCTION
“[C]oast through your next study.”1 Coast Institutional Review Board
(IRB), a for-profit company, offered a coupon, including this statement
informing potential customers that they could “coast” through any study
review, on its website for a free IRB review of a research protocol.2 True to its
word, Coast IRB allowed customers to coast through IRB review.3 In 2009,
Coast IRB unanimously approved a study involving a fictitious medical
product from a fictitious investigator at a fictitious company.4 This bogus
medical product was derived from a real product that the Food and Drug
Administration (FDA) pulled from the market after it killed human researchsubjects.5 In fact, two other IRBs rejected the fictitious study, while claiming
that the study was “the worst thing I have ever seen” and was “a terrible risk
for the patient.”6 In August 2011, just two years after the Coast IRB incident,
Essex IRB fell into a similar trap.7 Essex IRB, another for-profit IRB,

1. Coast Institutional Review Board’s coupon enticed customers to use its services by
implying its review of the study will be easy for the customer. Institutional Review Boards That
Oversee Experimental Human Testing for Profit: Hearing Before the Subcomm. on Oversight and
Investigations of the Comm. on Energy and Commerce, 111th Cong. 2–3 (2009) [hereinafter
Hearing on IRBs] (statement of Rep. Bart Stupak, Chairman, Comm. on Energy and Commerce).
This hearing has not been discussed in any legal journal articles regarding IRBs.
2. Id.
3. See e.g., Alicia Mundy, Sting Operation Exposes Gaps in Oversight of Human
Experiments, WALL ST. J. (Mar. 26, 2009), http://online.wsj.com/article/SB1238111795723531
81.html.
4. See id.
5. Hearing on IRBs, supra note 1, at 2 (statement of Rep. Bart Stupak, Chairman, Comm.
on Energy and Commerce).
6. Id.
7. Inspectional Observations, U.S. Dep’t of Health and Human Servs. Food & Drug
Admin., Form FDA 483 (Mar. 14–21, 2011), http://www.circare.org/fdawls/essexirb_fdafoia_
2011-6068.pdf.
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approved a similar bogus study using the same fictitious investigator from the
2009 sting operation.8
IRBs are the formal entities, regulated by the Department of Health and
Human Services (HHS), responsible for reviewing research involving human
subjects.9 All federally funded human subjects research and all FDA regulated
studies must be approved by an IRB.10 An IRB’s primary purpose is to “protect
the rights and welfare of human research subjects” by approving, modifying, or
rejecting human research studies.11 IRBs have a duty to assure researchsubjects that all study risks are fully disclosed, that all risks will be minimized
to the extent possible, and that all risks are appropriate in relation to any
anticipated benefits.12
Originally, the Office for Protection from Research Risks (OPRR) allowed
only IRBs located in or supported by institutions to review federally funded
studies.13 These institutionally supported IRBs, composed primarily of
members from the research institution, are referred to as “local IRBs.”14
Subsequently, in 1996, OPRR changed its position to allow IRBs that are
unaffiliated with the institution engaged in research to review federally funded
studies.15 These unaffiliated IRBs are referred to as “independent IRBs.”16
Currently, the Office of Human Research Protections (OHRP)—which
replaced OPRR in 200017—allows an institution to choose whether to use its
local IRB or to rely on the review of another, qualified IRB.18 However, on
July 26, 2011, HHS and the Office of Science and Technology Policy (OSTP)
issued proposed regulations for “Streamlining IRB Review of Multi-Site
Studies,” which suggest mandating a central IRB for multi-site studies in order
to strengthen protection for research subjects.19 A “central IRB” is a single IRB

8. Id.
9. U.S. DEP’T OF HEALTH & HUMAN SERVS., Chapter 1: Institutional Administration, in
INSTITUTIONAL REVIEW BOARD GUIDEBOOK 1 (1993), available at http://www.hhs.gov/ohrp/ar
chive/irb/irb_chapter1.htm.
10. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512–13 (proposed July
26, 2011); Institutional Review Boards, 21 C.F.R. § 56.103(a) (2012).
11. U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 9, at 1.
12. U.S. DEP’T OF HEALTH & HUMAN SERVS., Chapter 3: Basic IRB Review, in
INSTITUTIONAL REVIEW BOARD GUIDEBOOK, supra note 9, at 2.
13. David Forster, Independent Institutional Review Boards, 32 SETON HALL L. REV. 513,
517 (2002).
14. Id. at 515.
15. Id. at 517–18.
16. Id.
17. Office of Public Health and Science, 65 Fed. Reg. 37,136 (June 13, 2000).
18. Protection of Human Subjects, 45 C.F.R. § 46.114 (2011).
19. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512, 44,521 (proposed
July 26, 2011). The proposed regulations cover seven topics: “Ensuring Risk-Based Protections,
Streamlining IRB Review of Multi-Site Studies, Improving Informed Consent, Strengthening
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that reviews a study that will take place at multiple research sites and whose
review will supplant the local IRB’s review on the study.20
This note will argue, by analyzing the proposed regulations and their
implications for research-subjects’ protection, that forcing a research site to use
a central IRB does not strengthen protection for research subjects.21 Due to the
challenges imposed on a local IRB to approve and monitor the many
institutions in a multi-site study, these proposed regulations are effectively
forcing institutions to use an independent IRB.22 Since the majority of
independent IRBs are for-profit IRBs,23 these regulations will push IRB review
to for-profit companies, companies like Coast IRB and Essex IRB. For-profit
IRBs do not operate in the best interests of the research subjects because they
have greater incentives, namely income, to approve research proposals, as
illustrated in the Coast IRB and Essex IRB cases.24 Additionally, for-profit
IRBs have a conflict of interest because their sole source of income is the fees
paid by the sponsors, the companies backing the study, writing the research
protocol, and investing in this protocol’s approval.25 As a result, under the
proposed regulations, research subjects face a greater risk of participating in
potentially harmful studies.26

Data Protections to Minimize Information Risks, Data Collection to Enhance System Oversight,
Extension of Federal Regulations, and Clarifying and Harmonizing Regulatory Requirements and
Agency Guidance.” Id. at 44,512.
20. Id. at 44,522.
21. This note will focus on biomedical and pharmaceutical clinical trials. Distinguishing
between biomedical and behavioral research is necessary in order to know which activities need
to be reviewed. THE NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, THE BELMONT REPORT 10 (1979), available at http://www.fda.gov/ohr
ms/dockets/ac/05/briefing/2005-4178b_09_02_Belmont%20Report.pdf
(stating
“problems
relating to social experimentation may differ substantially from those of biomedical and
behavioral research”). Additionally, social scientists see social science research as fitting poorly
into the “medically-driven IRB protocol templates and language.” Caroline H. Bledsoe et al.,
Regulating Creativity: Research and Survival in the IRB Iron Cage, 101 NW. U. L. REV. 593,
596–97 (2007). Furthermore, FDA regulation of devices requires the use of local institutional
review committees in the same facilities as where the testing of the device is to occur. See also
Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,521 (proposed July 26, 2011)
(stating that the proposed regulations not apply to FDA-regulated device studies). Therefore, this
analysis does not pertain to behavioral research or medical device research.
22. See infra text accompany notes 133–63.
23. Compare Ruth Macklin, How Independent Are IRBs?, IRB: ETHICS & HUMAN
RESEARCH, May–June 2008, at 15, 19 (2008) (stating that there are some not for profit
independent IRBs, but that information on them is scarce), with Commercial Institutional Review
Boards, CITIZENS FOR RESPONSIBLE CARE AND RESEARCH, http://www.circare.org/info/commer
cialirb.htm (last visited Apr. 19, 2013) (listing forty-nine active commercial IRBs).
24. See infra text accompanying notes 221–42.
25. See infra text accompanying notes 221–32.
26. See infra text accompanying notes 213–45.
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The first section examines the history of research-subjects’ protection, the
proposed regulations, and the current legal issues involving IRB review. The
second section explains why the proposed regulations will essentially push
IRB review to independent IRBs and why independent IRBs do not act in the
research-subjects’ best interests. The final section makes suggestions for
improving research-subjects protection if the ultimate HHS regulations include
this central IRB provision.
I. UNDERSTANDING INSTITUTIONAL REVIEW BOARDS AND THE PROPOSED
REGULATIONS
A.

History of Regulating Research-Subjects’ Protection

Both the International community and the United States developed
regulations to protect research subjects in response to subject abuse in
“scientific” experiments. The Nuremberg Code, which was enacted in 1949 in
response to Nazi experimentation on concentration camp prisoners,27
developed the basic principles of ethical conduct for research involving human
subjects and specified ten “Directives for Human Experimentation.”28 In 1964,
the World Medical Association adopted similar recommendations in the
Declaration of Helsinki.29 Among other requirements, the Declaration of
Helsinki mandates that research ethics committees be “independent of the
researcher, the sponsor, and any other undue influences.”30 Although the
United States adopted many of these directives when creating its own researchsubjects’ protection regulations,31 the United States has not expressly adopted

27. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26,
2011); THE NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, supra note 21, at 2.
28. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26,
2011); The Nuremberg Code, NATIONAL INSTITUTES OF HEALTH, available at http://history.nih.
gov/research/downloads/nuremberg.pdf. The ten directives mandate voluntary consent,
experiments be for the good of society, experiments have anticipated results that justify the
performance, experiments that avoid unnecessary physical and mental pain, experiments that will
not knowingly result in subject death or disabling injury, experiments whose importance
outweighs risks to subjects, protection against remote possibilities of injury or death, experiments
conducted only by qualified personnel, subject autonomy to end a study at any point, and scientist
agreement to terminate an experiment if it is likely to result in injury, disability, or death of the
subject. Id.
29. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26,
2011).
30. World Medical Association Declaration of Helsinki: Ethical Principles for Medical
Research Involving Humans, WORLD MEDICAL ASSOCIATION, para. 15, http://www.wma.net/en/
30publications/10policies/b3/17c.pdf (last visited Apr. 19, 2013).
31. Compare The Nuremberg Code, supra note 28 (requiring voluntary consent and
continued observation after initial approval), with Protection of Human Subjects, 45 C.F.R. §
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all of the provisions of the Nuremberg Code and the Declaration of Helsinki.32
Furthermore, United States courts have varied in their application of the
Nuremberg Code to cases involving injured research subjects.33 In contrast,
courts have consistently concluded that the Declaration of Helsinki does not
apply in the United States.34
Before the United States developed its own research-subjects’ protection
regulations, astounding research abuses occurred on United States soil:
deliberately denying treatment to men with syphilis,35 injecting plutonium into
unsuspecting hospital patients,36 purposefully infecting children with

46.116 (2011) (mandating subject’s legally effective informed consent for subject’s involvement
in research experiment), and Protection of Human Subjects, 45 C.F.R. § 46.109(e) (2011)
(requiring continuing review of a study at least once a year).
32. Compare The Nuremberg Code, supra note 28 (necessitating the risk to never exceed the
humanitarian importance of the problem to be solved by the experiment), and World Medical
Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Humans,
supra note 30, para. 24 (requiring subjects be adequately informed of sources of funding, any
possible conflicts of interest, and any other relevant aspects of the study), with Protection of
Human Subjects, 45 C.F.R. § 46.101 (2011).
33. Compare Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 835 (Md. Ct. App. 2001)
(finding the Nuremberg Code to be the “most complete and authoritative statement of the law of
informed consent to human experimentation” and that “absence of judicial precedent makes
codes, especially judicially-crafted codes like the Nuremberg Code, all the more important”), with
Robertson v. McGee, No. 01-CV-60-C, 2002 U.S. Dist. LEXIS 4072, at *9 (D. Okla. Jan. 28,
2002) (stating that the court agrees that there is “no private right of action for an alleged violation
of international law” under the Nuremberg Code). Resorting to international law is unnecessary
when there is a standard in the Code of Federal Regulations. Id. at *9–*10.
34. Sykes v. United States, No. 1:10-CV-688, 2011 U.S. Dist. LEXIS 94815, at *9, *45 (D.
Ohio July 22, 2011) (holding that there was no private right of action for alleged violation of the
Helsinki Declaration in a case where a human subject allegedly died from pharmaceuticals given
in a clinical trial because the Code of Federal Regulations governs human subjects research in the
United States). See also White v. Paulsen, 997 F. Supp. 1380, 1383 (D. Wash. 1998); Hoover v.
West Virginia Dep’t. of Health & Human Services, 984 F. Supp. 978, 980 (D. W.Va. 1997);
Abdullahi v. Pfizer, Inc., No. 01 Civ. 8118, 2005 U.S. Dist. LEXIS 16126, at *31 (D. N.Y. Aug.
09, 2005).
35. From 1932-1972, the United States Public Health Service documented the natural history
of syphilis, using 399 black sharecroppers infected with syphilis, in the Tuskegee Syphilis Study.
CARL H. COLEMAN ET AL., THE ETHICS AND REGULATION OF RESEARCH WITH HUMAN
SUBJECTS 41 (2005). Not only did the physicians deny treatment to the men with syphilis, even
after the effective treatment of penicillin became available, but they also went to “extreme lengths
to ensure that they would not receive therapy from other sources.” Id. at 41.
36. From 1944–1974, the federal government funded radiation experiments where
physicians “inject[ed] plutonium into unsuspecting hospital patients” and released radiation into
the environment. Id. at 44. Several patients died from acute radiation effects. Id. In addition, the
government did not maintain adequate records in order to keep the public from learning about
these programs. Id. at 45.
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hepatitis,37 and injecting live cancer cells into elderly patients.38 Following
these highly publicized cases of research abuse, United States federal agencies
enacted the 1974 Research Act.39 In 1979, the National Commission published
its own guidelines for research-subjects’ protection in the Belmont Report.40
The Belmont Report provided a framework to guide the resolution of ethical
problems arising in human-subjects’ research.41 In addition to the Belmont
Report, in 1981, the FDA created provisions requiring IRB approval during the
FDA clinical investigation procedure, which include IRB review of clinical
investigations and of continuing review.42 Continuing review is the process of
periodically reviewing a study after the initial approval.43 Subsequently, in
1991, fourteen federal departments joined with HHS to adopt uniform rules,
known as the Common Rule, for the protection of research subjects.44 The
Common Rule covers all federally conducted or supported human-subjects
research.45
The Common Rule documents IRB member requirements: a minimum of
five members with varying backgrounds, a minimum of one member with a
primary scientific area of concern, a minimum of one member with a primary
nonscientific area of concern, and a minimum of one member not affiliated
with the institution.46 The Common Rule requires IRB member diversification
in order for its members to have sufficient experience and expertise to

37. From 1956–1971, Doctor Saul Krugman “fed extracts of stools from [hepatitis] infected
[institutionalized] children” as well as injected children with the hepatitis virus in order to study
the hepatitis virus. Id. at 39.
38. In 1963, the NIH and the Public Health Service funded a study where physicians
“injected live cancer cells into twenty-two indigent, chronically ill, and debilitated [and
unsuspecting] elderly patients at the Brooklyn Jewish Chronic Disease Hospital.” Id. at 39.
39. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26,
2011). This Act created the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research (National Commission). Id.
40. Id.
41. THE NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, supra note 21, at 3.
42. Protection of Human Subjects, 46 Fed. Reg. 8,958 (January 27, 1981) (codified at 21
C.F.R. § 56.101); 21 C.F.R. § 56.103(a) (2012).
43. 21 C.F.R. § 56.103(a) (2012).
44. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26,
2011). The Common Rule adopted 45 C.F.R. Part 46 Subpart A of the HHS regulations. Id. A
total of seventeen federal agencies now follow some form of the Common Rule. U.S. GOV’T
ACCOUNTABILITY OFFICE, GAO-09-448T, HUMAN SUBJECTS RESEARCH: UNDERCOVER TESTS
SHOW THE INSTITUTIONAL REVIEW BOARD SYSTEM IS VULNERABLE TO UNETHICAL
MANIPULATION 6 (2009).
45. Protection of Human Subjects, 45 C.F.R. § 46.101(a) (2011).
46. 45 C.F.R. § 46.107(a), (c), (d). The FDA’s IRB member requirements match those of the
Common Rule. See Institutional Review Boards, 21 C.F.R. § 56.107 (2012).
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safeguard the rights and welfare of research subjects.47 Additionally, the
Common Rule mandates that IRBs provide continued review of studies at least
once per year.48 The last major addition to research-subjects’ regulations came
in 2009 when HHS required each IRB reviewing research conducted or
supported by HHS to be registered with HHS.49
B.

Proposed Regulations: “Enhancing Protection for Research Subjects and
Reducing Burden, Delay, and Ambiguity for Investigators”

When the current regulations were developed, research generally took
place at single sites, predominantly universities, colleges, and medical
institutions.50 Presently, however, a substantial portion of research occurs in
multi-site studies at centers unaffiliated with these academic research
institutions.51 Multi-site studies, studies where a single research protocol is
conducted at numerous research sites, are particularly common in clinical
trials.52 This change in research dynamics is partially due to the shift in clinical
trial funding from the government to pharmaceutical companies53 and to the
need of these trials to generate sufficient participant numbers and generalizable
results.54 Research-subjects’ protection regulations, on the other hand, have not
evolved along with the proliferation of multi-site clinical trials.55 While the
Common Rule does not require separate approval from every local IRB in a
multi-site study, in many of these studies each institution’s local IRB will
review the research protocol independently, resulting in duplicative reviews of

47. Protection of Human Subjects, 45 C.F.R. § 46.103(b)(3) (2011).
48. 45 C.F.R. § 46.109(e). The IRB has the discretion to determine the frequency of
continuing review. Id. However, in determining this frequency, the IRB is to consider the degree
of risk. Id.
49. 45 C.F.R. § 46.501. This registration must be renewed every three years. Id. at §
46.505(a).
50. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26,
2011).
51. Id. at 44,521; Trudo Lemmens & Benjamin Freedman, Ethics Review for Sale? Conflict
of Interest and Commercial Research Review Boards, 78 MILBANK Q. 547, 548–49 (2000)
(stating that research of new drugs is increasingly taking place at pharmaceutical research centers
or physicians’ offices independent of academic research centers).
52. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,521 (proposed July 26,
2011).
53. Lynn A. Jansen, Local IRBs, Multicenter Trials, and the Ethics of Internal Amendments,
27 IRB: ETHICS & HUM. RES. 7, 7 (2005).
54. William Burman & Robert Daum, Grinding to a Halt: The Effects of the Increasing
Regulatory Burden on Research and Quality Improvement Efforts, 49 CLINICAL INFECTIOUS
DISEASES 328, 330 (2009).
55. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26,
2011).
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study protocols.56 Further delaying the research process, investigators must
resubmit any IRB protocol changes made by a local IRB to all reviewing
IRBs.57 For these reasons, critics have argued that the highly regulated IRB
review structure hinders the research process by creating inefficiencies and
adding bureaucratic complexity with duplicative IRB review.58 These critics
have claimed that research is unnecessarily delayed, since there is no evidence
that research subjects are protected by the multiple reviews.59 Conversely, the
absence of evidence, especially in the absence of any research focusing on the
safety of these reviews, is not a reasonable argument to change regulations.
Duplicative reviews of studies provide additional scrutiny of research protocols
for the primary goal of protecting research subjects. Until more research is
performed, there is no evidence to demonstrate that removal of these additional
reviews will benefit research subjects. However, in response to the critics,
HHS proposed new human subjects research protection regulations.60
1. Proposed Regulations
On July 26, 2011, HHS and OSTP proposed regulations to strengthen
protection for research subjects and to match the “evolving human research
enterprise [and] the proliferation of multi-site clinical trials.”61 HHS and OSTP
requested comments to the proposed regulations be submitted before October
26, 2011.62 As of the date of this note, the proposed regulations are closed for
commenting, and HHS has yet to release final regulations.63
The proposed regulations mandate “that all domestic sites in a multi-site
study rely upon a single IRB as their IRB of record for that study,”64 meaning
the regulations require the use of a central IRB for multi-site studies. This is a
change from the current regulations, which give institutions a choice in

56. Id. at 44,521, 44,522.
57. Id.
58. Id. at 44,513.
59. Id.
60. Id. at 44,512.
61. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26,
2011).
62. Initial comment deadline was September 26, 2011. Human Subjects Research
Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26, 2011). HHS and OSTP extended the
deadline to October 26, 2011 after multiple requests for extensions. Advanced Notice of Public
Rule Making, U.S. DEP’T OF HEALTH & HUMAN SERVS., http://www.hhs.gov/ohrp/humansub
jects/index.html (last visited Apr. 19, 2013).
63. Information Related to Advanced Notice of Proposed Rulemaking (ANPRM) for
Revisions to the Common Rule, U.S. DEP’T OF HEALTH & HUMAN SERVS., http://www.hhs.gov/
ohrp/humansubjects/anprm2011page.html (last visited Apr. 19, 2013).
64. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,522 (proposed July 26,
2011).
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deciding whether to use a central IRB or their own IRB in multi-site studies.65
The regulations do not suggest guidelines for how to select the IRB of record,
but the regulations seemingly give the sponsor unfettered discretion to choose
the IRB of record for multi-site studies.66 Complete sponsor discretion poses a
serious concern for research-subjects’ interests, since research subjects place
trust in an unbiased IRB to protect their welfare. Additionally, while local sites
would not be relieved of any obligations under the research-subjects’
protection regulations, local internal reviews could be discouraged and would
not have regulatory status with the Common Rule under the proposed
regulations.67 Therefore, local IRB review may be limited, if at all necessary,
to perspectives of the local community:68 cultural backgrounds of the research
subjects’ population, community attitudes about the proposed research, and the
capacity of the institution to support the proposed research.69 However, even
this review may be limited as the proposed regulations suggest, in contrast to
previous regulations, that “[t]he evaluation of a study’s social value, scientific
validity, and risks and benefits, and the adequacy of the informed consent
document and process generally do not require the unique perspective of a
local IRB.”70
2. HHS Support for Proposed Regulations
In addition to HHS and OSTP opinions on the need for central IRB review
of multi-site studies, the proposed regulations cited recent academic journal
articles in support of the new regulations. These studies highlight concerns
with research integrity, site-specific modifications, and variability among local
IRB review.71 Multiple reviews of multi-site studies can affect research
integrity when IRB reviews produce different outcomes for identical studies.72

65. Id.
66. Id. at 44,521–22. See also Janet M. Lis & Melina G. Murray, The Ins and Outs of
Independent IRBs, 2 J. HEALTH & LIFE SCI. 73, 79 (2008).
67. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,522 (proposed July 26,
2011).
68. Id.
69. U.S. DEP’T HEALTH & HUMAN SERVS. ET AL., GUIDANCE FOR INDUSTRY: USING A
CENTRALIZED IRB REVIEW PROCESS IN MULTICENTER CLINICAL TRIALS 4–5 (2006) [hereinafter
GUIDANCE FOR INDUSTRY].
70. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,522 (proposed July 26,
2011). Contra Protection of Human Subjects, 45 C.F.R. § 46.107(a) (2011) (stating the point of
local IRBs is to gain the perspective of the community and for researchers to demonstrate the
input of local comments on the requirements for a waiver of consent).
71. Kathleen Dziak et al., Variations Among Institutional Review Board Reviews in a
Multisite Health Services Research Study, 40 HEALTH SERVS. RES. 279, 287 (2005).
72. Human Subjects Research Protection, 76 Fed. Reg. 44,512, 44,522 (proposed July 26,
2011); Dziak et al, supra note 71, at 282–83 (examining a study evaluating patient perceptions of
care at fifteen primary sites). See also Jansen, supra note 53, at 7.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

420

SAINT LOUIS UNIVERSITY PUBLIC LAW REVIEW

[Vol. XXXII:411

Research integrity deals with verifiable methods in research and the adherence
to rules, regulations, and guidelines in research.73 In addition to producing
different outcomes, local IRBs sometimes made minor, site-specific
modifications during local review of multi-site studies.74 These site-specific
modifications can potentially undermine the scientific validity of a study
because they introduce an uncontrolled variance.75 Another concern is the
approval time discrepancy from institution to institution.76 The variability in
the IRB approval process is cited as an “enormous challenge” to humansubjects’ research.77
Along with the concerns regarding multiple IRB reviews of a single
protocol, HHS supported the central IRB mandate by suggesting that local
review is not necessary and does not add protection for subjects.78 HHS cited
to a report that found that there is no data to show that local perspectives are
taken into consideration during local IRB review.79 Additionally, critics of the
current system support the notion that a mandatory central IRB review would
create a stronger local IRB system,80 since multiple reviews divert IRB
resources from other studies.81 Along with retaining valuable resources, critics
suggest that independent IRBs are less vulnerable to institutional pressures.82
However, these challenges pit the interests of scientific research against the
interests of human-subjects’ welfare. Although there is no evidence that
additional local review helps protect subjects, clearly additional local review
does not place subjects at a greater of risk of being injured in research studies.
Additionally, these critics fail to address the serious implication that

73. Research Integrity, U.S. DEP’T HEALTH & HUMAN SERVS., http://grants.nih.gov/grants/
research_integrity/index.htm (last visited Apr. 19, 2013).
74. Jansen, supra note 53, at 7.
75. Id. at 8.
76. Dziak et al., supra note 71, at 283. The time it took for the fifteen IRBs to review the
study ranged from five to 172 days. Id. HHS also cited to a report that indicated that the review
time variability concerned study sponsors. Human Subjects Research Protection, 76 Fed. Reg.
44,512, 44,522 (proposed July 26, 2011); NAT’L INST. OF HEALTH ET AL., NATIONAL
CONFERENCE ON ALTERNATIVE IRB MODELS: OPTIMIZING HUMAN SUBJECT PROTECTION 6
(2006), available at https://www.aamc.org/download/75240/data/irbconf06rpt.pdf [hereinafter
NATIONAL CONFERENCE].
77. Dziak et al., supra note 71, at 287.
78. Human Subjects Research Protection, 76 Fed. Reg. 44,512, 44,522 (proposed July 26,
2011).
79. Ezekiel J. Emanuel et al., Oversight of Human Participants Research: Identifying
Problems to Evaluate Reform Proposals, 141 ANN. INTERNAL MED. 282, 283 (2004).
80. Id. at 289. Reducing the burden on local IRBs would allow them to “focus on research
requiring a local perspective.” Id. at 287.
81. Burman & Daum, supra note 54, at 330–31 (finding that a multi-site study required a
median of thirty staff hours).
82. NATIONAL CONFERENCE, supra note 76, at 5.
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independent IRBs are more vulnerable to sponsor pressure, since the sponsor is
the IRB’s customer.83 While HHS’s rationale suggests that the regulations
protect important research integrity issues, the proposed regulations were not
based on any factual studies showing that a central IRB would improve
research-subjects’ safety.84
C. Recent Issues with IRBs: Why the Public Should Care About Research
Subject Protection Regulations
IRBs exist in order to protect research-subjects’ safety.85 Improving
subject safety should be the top priority for new HHS regulations, especially
given the track record of research-subjects’ protection.
1. Research Subject Injuries: Effective IRB Regulations are Essential to
Protecting Research Volunteers
Research abuses still occur in the United States despite HHS regulations
and IRB review of studies.86 Risks exist for any clinical trial participant, but
recent cases of participant injury or death place into question whether financial
conflicts of interest put subjects in a greater position of risk.87 While the more
publicized research deaths may have occurred in studies governed by local
IRBs,88 research subjects have been injured in studies governed by for-profit
IRBs as well.89
Perhaps the most publicized participant injury in recent years was the death
of 18-year old Jesse Gelsinger at the University of Pennsylvania in 1999
during a gene-therapy trial.90 The informed consent form Gelsinger signed
failed to mention that several monkeys had died in a prior study91 and that four
research subjects previously suffered severe liver damage.92 Unfortunately,
Gelsinger’s death has not been an isolated incident where oversight has failed
83. See infra text accompanying notes 221–32.
84. Human Subjects Research Protection, 76 Fed. Reg. 44,512, 44,521–22 (proposed July
26, 2011).
85. Institutional Review Boards, 74 Fed. Reg. 9,578 (proposed March 5, 2009) (to be
codified at 45 C.F.R. pt. 46).
86. See infra text accompanying notes 91–105.
87. See infra text accompanying notes 98–105.
88. Commentators have pointed out that the highly publicized cases of human subjects
injuries have been in single-site studies. Burman & Daum, supra note 54, at 332.
89. Ezekiel J. Emanuel et al., Should Society Allow Research Ethics Boards to Be Run as
For-Profit Enterprises?, 3 PLOS MED. 941, 943 (2006).
90. Robin Fretwell Wilson, Estate of Gelsinger v. Trustees of University of Pennsylvania:
Money, Prestige, and Conflicts of Interest in Human Subjects Research, in HEALTH LAW AND
BIOETHICS 229, 229 (Sandra H. Johnson et. al. eds., 2009).
91. Id.
92. Sharona Hoffman, Continued Concern: Human Subject Protection, the Institutional
Review Board, and Continuing Review, 68 TENN. L. REV. 725, 725 (2001).
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to protect research subjects. Not long after Gelsinger’s death, Ellen Roche, a
healthy volunteer, died in an asthma study conducted by Johns Hopkins
University.93 Following Roche’s death, the FDA concluded that the study’s
IRB review was “inadequate” 94 and suspended all federally-funded research at
John Hopkins.95 These are just two cases that demonstrate how things can go
wrong at prominent research institutions under local IRB review when the IRB
and the researchers lose sight of their priority to protect research subjects.96
Although less publicized, independent IRBs and multi-site studies have
had recent issues with injured subjects as well. In 2002, Gary Polsgrove died
twenty-two days after enrolling in a study at the Fabre Research Clinic in
Houston.97 A Fabre Clinic employee, an employee represented to the FDA as a
licensed physician’s assistant, with no actual medical training, was responsible
for Polsgrove’s care during the study.98 The IRB reviewing the study—the
Human Investigation Committee—was run by Fabre, the same man who ran
the research clinic.99 This “IRB held its meetings in restaurants around
Houston.”100 Even though the FDA issued a warning to the IRB in 1992
highlighting its conflict of interest, the IRB continued to review studies at the
Fabre Clinic, including the study in which Polsgrove was enrolled.101 In 2004,
93. Hazel Glenn Beh, The Role of Institutional Review Boards in Protecting Human
Subjects: Are We Really Ready to Fix a Broken System?, 26 LAW & PSYCHOL. REV. 1, 32 (2002).
Ellen Roche died on June 3, 2001. Id.
94. Jonathan Bor & Tom Pelton, U.S. Halts Hopkins Research, THE BALTIMORE SUN (July
20, 2001), http://www.baltimoresun.com/bal-te.hopkins20jul20,0,5166731.story.
95. Beh, supra note 93, at 32.
96. Daniel L. Icenogle & Whyte H. Dudek, IRBs, Conflicts and Liability: Will We See IRBs
in Court? Or is it When?, 1 CLINICAL MED. & RES. 63, 64 (2002). Other stories include Kathryn
Hamilton’s death in a breast cancer study at the renowned Fred Hutchinson Cancer Center and
nine-month-old Gage Steven’s death in a heartburn study at Pittsburgh Children’s Hospital. Duff
Wilson & David Heath, With a Year or Two to Live, Woman Joined Test in Which She was
Misled-and Died, SEATTLE TIMES (Mar. 13, 2001), http://community.seattletimes.nwsource.com/
archive/?date=20010313&slug=hutch13; Dawn MacKeen, Kids as Guinea Pigs, SALON (May 31,
2000), http://www.salon.com/2000/05/31/drug_trials/. The shocking part about Hamilton’s story
is that only six days after Hamilton passed, her doctors published a study concluding that the
drugs did not work. Wilson & Heath, supra note 96.
97. DAVID EVANS ET AL., BLOOMBERG MARKETS, BIG PHARMA’S SHAMEFUL SECRET 4
(2005), available at http://dcscience.net/pharma-bloomberg.pdf.
98. Id. Astoundingly, a similar situation was uncovered in 2010 when Doctor Kamrava at
Napoli LLC conducted a clinical study that was approved by the local IRB at West Coast IVF
Clinic, of which Doctor Kamrava and an embryologist were the IRB’s only members. Letter from
Steven D. Silverman, Dir., Ctr. for Devices and Radiological Health, to Michael M. Kamrava,
Chairman, Int’l Review Bd. (Jan. 21, 2011) (on file with the U.S. Dep’t of Health & Human
Servs.), available at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2011/ucm2
40960.htm.
99. EVANS ET AL., supra note 97, at 4.
100. Id.
101. Id.
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Western IRB, the nation’s largest for-profit IRB,102 settled a lawsuit with a
research subject for an undisclosed amount after the subject, whose psoriatic
arthritis was under control before the study, became so ill during the study that
he could barely walk or stand.103 Other injuries in multi-site studies include the
death of a 19-year old University of Rochester student in a Massachusetts
Institute of Technology study.104 In addition to these notorious injuries and
deaths, research-subjects’ injuries have prompted lawsuits against IRBs.105
2. IRB Liability: Can IRBs Be Held Liable for Failing to Protect
Research Subjects?
Neither the OHRP nor the FDA can require an institution or an IRB to pay
damages to an injured research subject.106 Although injured research subjects
have been suing institutions and researchers for a long time, litigation against
IRBs has increased in the past decade.107 Although injured participants have
not won a court verdict against an IRB, there are cases where IRBs, including
for-profit IRBs, have settled with plaintiffs outside of the courtroom.108
However, this lack of success in the courtroom has not deterred plaintiffs from
adding IRBs and individual IRB members as defendants to lawsuits. 109
Injured research subjects first opened the door to suing IRB members in
Robertson v. McGee.110 Robertson arose out of a study at the University of
Oklahoma Health Science Center.111 The plaintiffs alleged that the “IRB
members failed to examine the design of the protocol, review the operation of
the trial, review proposed amendments to the informed consent forms, review

102. Caroline McNeil, Debate Over Institutional Review Boards Continues as Alternative
Options Emerge, 99 J. NAT’L CANCER INST. 502, 502 (2007).
103. EVANS ET AL., supra note 97, at 6.
104. Dan McGuire, Rochester Death Halts MIT Funded Study, THE TECH, April 9, 1996,
available at http://tech.mit.edu/V116/PDF/N17.pdf.
105. Marjorie Ellen Zettler, Trials and Tribulations of the IRB Member, 80 U. TORONTO
MED. J. 200, 200–01 (2003).
106. Sharona Hoffman & Jessica Wilen Berg, The Suitability of IRB Liability, 67 U. PITT. L.
REV. 365, 416 (2005).
107. See id. at 382–84; See Zettler, supra note 105, at 201.
108. EVANS ET AL., supra note 97, at 6 (disclosing that Western IRB settled with Bill Hamlet
for an undisclosed amount); Hoffman & Berg, supra note 106, at 382; Beh, supra note 93, at 29,
31–32 (disclosing the University of Pennsylvania settled with the Gelsinger family after Jesse
Gelsinger’s death).
109. See generally, infra text accompanying notes 114–17; see also T.C. ex rel. v. A.I.
DuPont Hosp. for Children, 368 F. App’x 285, 286–87 (3d Cir. 2010); M.G. ex rel. v. A.I.
DuPont Hosp. for Children, 393 F. App’x 884, 885–86 (3d Cir. 2010).
110. Hoffman & Berg, supra note 106, at 383.
111. Robertson v. McGee, No. 01-CV-60-C, 2002, U.S. Dist. LEXIS 4072, at *5 (D. Okla.
Jan. 28, 2002).
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amendments to the protocol, and ensure proper reporting.”112 However, the
Robertson court did not issue a ruling on the merits because the court
concluded that it lacked subject-matter jurisdiction.113 Similarly, in Townsend
v. University Hospital-University of Colorado, a research subject’s family
members sued the individual members of the University of Colorado IRB after
the subject died in the hospital’s care.114 In this case, the IRB member liability
issue was not decided because the court lacked personal jurisdiction.115 In
addition to these decided IRB cases, there are also cases currently pending
against IRBs. An injured subject filed a complaint in April 2011 against the
individual members of an IRB for failing to use due care in approving a gene
therapy protocol.116 Another recently filed lawsuit against Duke University
took a different approach by suing Duke directly for negligence per se for its
IRB’s failure to “renew its review of the research as other renowned
researchers called the Duke University and/or DUHS Clinical Trials into
question.”117
Multiple theories have been proposed to hold IRBs liable for researchsubject injuries. IRB liability does not fall within typical liability grounds
because the IRB does not contract directly with research subjects or make
direct representations to them.118 Furthermore, the Common Rule does not
create a private right of action against an IRB.119 However, IRB members may
be found negligent for not taking precautions to ensure that protocols complied
with applicable regulations if the plaintiff can demonstrate causation and
damages.120 For example, in Kus v. Sherman Hospital, an Illinois Appellate
Court held that the IRB could be liable for negligence if it violated a statutory
duty imposed by federal regulations.121
Others have suggested filing claims against IRBs under the False Claims
Act (FCA), although no decisions have been reached on the merits against an

112. Icenogle & Dudek, supra note 96, at 65.
113. Robertson v. McGee, No. 01-CV-60-C, 2002, U.S. Dist. LEXIS 4072, at *13 (D. Okla.
Jan. 28, 2002).
114. Danielle C. Beasley, Coupling Responsibility with Liability: Why Institutional Review
Board Liability is Good Public Policy, 36 N. KY. L. REV. 45, 46 (2009).
115. Id.
116. Complaint at 32–33, Zeman v. Williams et al., 2011 WL 552700 (D. Mass. 2011) (No.
1:11-CV-10204).
117. Complaint & Demand for Jury Trial at 213, Aiken v. Duke Univ., et al., 2011 WL
4956867 (N.C. Super. 2011) (No. 11 CVS 4721).
118. NATIONAL CONFERENCE, supra note 76, at 15.
119. Id. at 16.
120. Beasley, supra note 114, at 59.
121. David B. Resnik, Liability for Institutional Review Boards, 25 J. OF LEGAL MED. 131,
142 (2004). The regulations do not differentiate between local and independent IRBs, so members
of independent IRBs could also be held liable for violating their statutory duty. Institutional
Review Boards, 21 C.F.R. § 56.107 (2012).
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IRB under the FCA.122 In order to file under the FCA alleging violations of the
Common Rule, a plaintiff must meet three conditions: “(1) the government,
specifically OHRP, is not aware of the violations; (2) the violations are
substantive, material to the government’s decision to fund, and not merely
technical; and (3) the IRB knew that the research violated the federal
regulations or was reckless in applying them.”123 Because the plaintiff need not
show personal injury, the FCA may be an attractive alternative when proof of
causation is challenging.124 One of the major benefits of the FCA is that
society can proactively fix “problem” IRBs instead of having to wait until a
research subject is seriously injured or killed in order to file a suit.125 However,
a plaintiff may have difficulty in this type of suit demonstrating that the IRB
presented a false claim or caused a false claim to be presented.126
Another avenue for recovery would be to consider injured research
subjects as third-party beneficiaries to the contract between the federal agency
and the research institution.127 The contract should be looked at as providing
the terms under which research protocols must be approved, instead of as a
contract to provide potential therapeutic benefits. Therefore, the research
subjects would be beneficiaries of this contract.128 Additionally, fiduciary
theory may be an attractive avenue for recovery if the plaintiffs find it
challenging to prove the elements of negligence.129 In this scenario, plaintiffs
would have to prove that IRB members are fiduciaries and to identify the IRB
members’ defined role.130
Not only have IRBs been able to escape liability for research decisions,
plaintiffs can also have trouble requesting IRB documents.131 The laws in some

122. Daniel J. Powell, Using the False Claims Act as a Basis for Institutional Review Board
Liability, 69 U. CHI. L. REV. 1399, 1400 (2002).
123. Id. at 1416.
124. Id.
125. Id. at 1419.
126. Hoffman & Berg, supra note 106, at 401–02.
127. Lori A. Alvino, Who’s Watching the Watchdogs? Responding to the Erosion of Research
Ethics by Enforcing Promises, 103 COLUM. L. REV. 893, 920–23 (2003).
128. Id. at 922.
129. Hoffman & Berg, supra note 106, at 394.
130. Id.
131. Dieffenbach v. United States, 715 F. Supp. 2d 587, 588 (D. Del. 2010). Defendant filed a
motion for a protective order covering documents generated through IRB review at the National
Lung and Blood Institute and the NIH. Id. The court found materials prepared with confidential
expectations to be privileged. Id. at 598. Any documents made publicly available were not given
the same protection. Id. Compare Doe v. Illinois Masonic Medical Center, 696 N.E.2d 707, 708
(Ill. App. Ct. 1998) (finding Illinois Masonic Medical Center to be protected under the Illinois
Medical Studies Act from disclosing IRB files and IRB meeting minutes), with Konrady v.
Oesterling, 149 F.R.D. 592, 595 (D. Minn. 1993) (holding that an IRB does not fall within the
Minnesota evidentiary shield for peer review). In Konrady, the court held that an IRB conducts
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states, like Illinois, place the priority in protecting IRBs and researchers over
protecting research subjects.132 This misalignment of priorities misses the point
of IRBs—IRBs exist to protect research subjects.
The fact that serious issues have occurred both with local IRBs and forprofit IRBs only highlights the issue that HHS’s system is not working to
protect research subjects. While inadequate ethics review is unacceptable, a
company making money off of reviewing its own research is morally
repugnant. Regulations should not push more studies toward for-profit
companies without safeguards in place to prevent this type of occurrence.
II. PROPOSED REGULATIONS DO NOT PLACE RESEARCH-SUBJECTS’
PROTECTION AS TOP PRIORITY
A.

Mandating Central IRB Review Effectively Means Overworked Local
IRBs Will Defer to Independent IRBs for Multi-Site Studies

The implications of the proposed regulations on research-subjects’ safety
are unknown, since no studies exist to show that central IRBs are better for
subject protection.133 However, the few studies on central IRBs that do exist
suggest that it would not be feasible for local IRBs to become the central IRB
for multi-site studies. With that being said, there is limited data from which to
draw these predictions because IRB databases are nonexistent.134
IRB operating costs vary substantially from IRB to IRB.135 Although total
IRB costs are debatable, there is consensus that local IRBs are overworked.136
Overworked local IRBs are not likely to want, nor are they likely to be able to,
take on the additional responsibility of overseeing multi-site reviews. Due to

“process review” rather than “peer review.” Dieffenbach, 715 F. Supp. 2d at 596. IRBs protect
human subjects by collecting and disseminating information about the studies, even to the public.
Id. The court in Illinois Masonic Medical Center noted that the Illinois statute was broader than
the Minnesota statute in Konrady. 696 N.E.2d at 710.
132. Illinois Masonic Medical Center, 696 N.E.2d at 711 (concluding that the IRB did not
have to release meeting notes because the “interests of litigants must yield to other interests, in
this case confidentiality, privacy and candid peer review within medical institutions”).
133. Human Subjects Research Protection, 76 Fed. Reg. 44,512, 44,522 (proposed July 26,
2011). If this type of study existed, HHS would have used it.
134. Todd H. Wagner et al., Economies of Scale in Institutional Review Boards, 42 MED.
CARE 817, 818 (2004). In order to improve IRBs, there is a need to develop standards of
measurement in order to actually evaluate IRB effectiveness and quality in protecting human
subjects, along with cost analysis. Margaret M. Byrne et al., Variability in the Costs of
Institutional Review Board Oversight, 81 ACAD. MED. 708, 712 (2006).
135. Byrne et al., supra note 134, at 711. The study used 2002 survey information to
determine the costs of activities. Id. at 709. Many institutional IRBs now charge commercial
sponsors for review. Emanuel et al., supra note 79, at 283.
136. Beh, supra note 93, at 35.
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limited IRB resources,137 taking on multi-site studies might steal valuable
resources away from institutional research studies. A single multi-site study
may capture a large portion of an IRB’s budget for multiple years.
Additionally, many institutions do not compensate their IRB members for
individual efforts,138 meaning any additional IRB work detracts from
members’ compensated duties. IRBs that are already struggling with providing
adequate continuing review139 are unlikely to take on studies with significantly
more challenging continuing review.
If a local IRB were to be the central IRB for a multi-site study, the time
costs of review and continuing review would be a concern. Although initial
review would be similar to a regular IRB review, the time cost would be
greater since the IRB would have to consider the local context at each site.140
Under 21 C.F.R. § 56.107(a), IRB members have to “ascertain the
acceptability of the proposed research in terms of institutional commitments
and regulations, applicable law, and standards or professional conduct and
practice.”141 The local IRB would have to become aware of local community
concerns at every site in the multi-site study and document these concerns in
meeting minutes.142 Relevant community concerns include local attitudes and
local research laws: laws on consent, laws on confidentiality relating to
substance abuse, laws on mental healthcare, and laws on HIV/AIDs status.143
Mechanisms for ensuring adequate local review could include forms, to be
filled out by individuals familiar with the local community, that request
relevant local information; consultant interviews; or requests for written input
from local IRB members at each site.144 Whichever mechanism is chosen, local
community concerns will provide a significant challenge for an unprepared
local IRB.
Local IRBs, which are familiar with reviewing studies where they know
the researchers,145 will have to spend time and money on training to learn how
to work with unfamiliar institutions, IRB members, and communities. The

137. IRBs have “inadequate resources, unmanageable workloads, and, in some cases,
insufficient expertise.” Hoffman, supra note 92, at 737.
138. Emanuel et al., supra note 79, at 283. See also, Jeremy Sugarman et al., The Cost of
Institutional Review Boards in Academic Medical Centers, 352 NEW ENG. J. MED. 1825, 1825
(2005) (finding 43 percent of institutions do not provide monetary compensation to IRB members
in a 2002 survey).
139. Hoffman, supra note 92, at 748–49.
140. GUIDANCE FOR INDUSTRY, supra note 69, at 2.
141. Institutional Review Boards, 21 C.F.R. § 56.107(a) (2001).
142. Wagner et al., supra note 134, at 817; GUIDANCE FOR INDUSTRY, supra note 69, at 5
(citing 21 C.F.R. § 56.115(a)).
143. Lis & Murray, supra note 66, at 98–102.
144. GUIDANCE FOR INDUSTRY, supra note 69, at 5.
145. Wagner et al., supra note 134, at 817.
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institutions may have conflicting policies and procedures, which would have to
be considered in order to preserve the ethical beliefs of each institution.146 For
example, Catholic institutions will have different rules than nondenominational institutions.147 In addition, there would be an added time cost
to familiarize IRB members with other states’ applicable laws.148 State laws
play an important role in research conduct,149 as federal regulations do not
override state laws, which provide additional protection for research
subjects.150 Since many IRBs do not have budgets, re-training staff members to
deal with off-site studies may be cost-prohibitive, time-prohibitive, and
undesirable.151
Continuing review will also be a major concern for local IRBs, and the
importance of continuing review cannot be overlooked.152 Separating the
reviewers from the research study site makes the IRB’s job in monitoring
research even more difficult.153 Since staff and board time costs are the
majority of IRB costs, the amount of staff and board hours to cover continuing
review of far-away institutions would significantly increase IRB costs.154 Local
IRBs may not have the resources to adequately review different sites.155 Not
only would travel time increase, but technology costs—faxes, phones, web
pages, databases—would likely increase as well for an IRB to sufficiently
review off-site locations.156 Since IRBs are already struggling with providing

146. NATIONAL CONFERENCE, supra note 76, at 4.
147. See CORNELL UNIVERSITY OFFICE OF RESEARCH INTEGRITY AND ASSURANCE HUMAN
RESEARCH PARTICIPANT PROTECTION PROGRAM, SOP 10: INFORMED CONSENT OPTIONS,
PROCESSES, AND DOCUMENTATION 1 (2010) (demonstrating an IRB can have final authority
regarding their own various policies).
148. Wagner et al., supra note 134, at 822.
149. COLEMAN ET AL., supra note 35, at 163. For example, California law requires
identification of the research sponsor, the funding source, or the name of the manufacturer. Id. at
166. Maryland law requires all human subjects research adhere to federal regulations. Emanuel et
al., supra note 79, at 283.
150. Protection of Human Research Subjects, 45 C.F.R. § 46.101(f) (2011).
151. Wagner et al., supra note 134, at 818. The cost of training each staff member averaged
$1,155. Id.
152. A thorough continuing review in the Gelsinger case might have focused on the serious
treatment side effects of other participants, possibly resulting in the IRB suspending the clinical
trial before his death. Hoffman, supra note 92, at 726. See also Kus v. Sherman Hosp., 644
N.E.2d 1214, 1218 (Ill. App. Ct. 1995) (stating, in a lawsuit against a hospital and not the IRB,
that continuing review of the study by the IRB in this case would have discovered modified
consent forms).
153. Lemmens & Freedman, supra note 51, at 573.
154. Byrne et al., supra note 134, at 711.
155. Wagner et al., supra note 134, at 820 (finding current continuing reviews to take up 12
percent of an IRB’s review time). This percentage of IRB time would increase significantly when
many more sites are added for continuing review.
156. Id. at 821–22.
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adequate continuing review,157 the daunting task of following-up at every
research site may be enough in itself to deter local IRBs from becoming central
IRBs for multi-site studies. Consequently, local IRBs may not desire to
become a central IRB for multi-site studies.
In addition to the burdens on the local IRB, there is no evidence that
sponsors would choose to work with local IRBs when turnaround time at
independent IRBs is significantly faster.158 In a recent study, initial review at
the National Cancer Institute (NCI) Central IRB averaged 7.9 hours, compared
to the mean time of 14 hours at local IRB sites.159 In addition to IRB staff time,
there was also a difference in the number of days it took to get the study
passed.160 At the central IRB site, the entire approval process took, on average,
28.3 days, while the approval process averaged 62.3 days at the local sites.161
Since sponsors value faster and more predictable reviews, they are willing to
pay to use independent IRBs.162 Because there are few nonprofit, independent
IRBs, the majority of the independent IRBs used by sponsors are for-profit
companies.163 While these for-profit IRBs may be more efficient for sponsors,
relying solely on independent IRBs for multi-site studies raises concerns
regarding the welfare of research subjects.

157. Seven out of nine IRBs sent FDA warning letters in 2011 were cited for failures relating
to continuing review. Inspections, Compliance, Enforcement, and Criminal Investigations, U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2011/de
fault.htm (last visited Apr. 19, 2013). In fact, one IRB was cited in both 2010 and 2011 for failing
to conduct continuing review. Letter from Leslie K. Ball, Dir., Food & Drug Admin., to Alice M.
Gerard, President & Chief Exec. Officer, Bay Regional Medical Center (Sept. 9, 2010) (on file
with the U.S. Dep’t of Health & Human Servs.), available at http://www.fda.gov/ICECI/Enforce
mentActions/WarningLetters/2010/ucm225596.htm; Letter from Leslie K. Ball, Dir. Food &
Drug Admin., to Philip Incarnati, President & Chief Exec. Officer, McLaren Health Care (Dec. 2,
2011) (on file with the U.S. Dep’t of Health & Human Servs.), available at http://www.fda.
gov/ICECI/EnforcementActions/WarningLetters/2011/ucm284969.htm. See also 1998 Office of
Inspector General statement criticizing IRBs for failing to provide adequate continuing review of
studies. Wagner et al., supra note 134, at 822.
158. One study found the average decision time for independent IRBs to be eleven days
compared with thirty-seven days for academic IRBs. Lis & Murray, supra note 66, at 87. See also
Todd H. Wagner et al., Costs and Benefits of the National Cancer Institute Central Institutional
Review Board, 28 J. OF CLINICAL ONCOLOGY 662, 664 (2010), available at http://www.ncbi.nlm.
nih.gov/pmc/articles/ PMC2816001/pdf/zlj662.pdf.
159. Wagner et al., supra note 158, at 664.
160. Id.
161. Id.
162. Id. at 665.
163. Compare Macklin, supra note 23, at 19 (stating that there are some not-for-profit
independent IRBs, but that information on them is scarce), with Commercial Institutional Review
Boards, supra note 23 (listing forty-six active commercial IRBs).
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Independent IRBs are not in the Research-Subjects’ Best Interests
1. Broken Independent IRBs

Although IRB subject safety issues are not isolated to independent IRBs,164
local IRB issues do not make for-profit IRB problems go away.165 The two
recent sting operations involving Coast IRB and Essex IRB illustrate major
concerns with mandating the use of central IRBs without any changes in
research-subjects’ protection or without requiring any additional oversight of
for-profit IRBs. As shocking as the Coast IRB incident was, the Essex IRB
incident was unnerving. HHS has not done anything in the past two years to
remedy the “rubber-stamping” highlighted in the Coast IRB sting operation.
In late 2008, the Government Accountability Office (GAO) created a fake
protocol, based on a study for a product that the FDA had removed from the
market after patient deaths, and submitted the protocol to three IRBs to
determine whether IRBs were “rubberstamping” research studies.166 Coast IRB
approved this protocol unanimously, 7-0.167 The other two IRBs, who rejected
the study protocol, commented that the study was “the most complicated thing
that I have ever seen” and was “a terrible risk for the patient.”168 They both
questioned patient safety in the protocol.169 Whereas, Coast IRB’s primary
reviewing doctor told the board members that the protocol “looks fine” and
that it was “probably very safe.”170 Furthermore, Coast IRB was only given
information on 2.5 percent of the product, and the board never asked what
made up the other 97.5 percent of the product that was to be placed in the
subject’s body.171 Coast IRB discovered the fraud only after being contacted
by congressional investigators five months after approval.172 Therefore,
experimentation with this deadly product could have been occurring on
research subjects for five months.173

164. IRB Seals Fate by Approving Fake Protocol in Federal Sting, IRB ADVISOR, July 1,
2009 (statement of Marjorie Speers, Executive Director, AAHRPP).
165. Emanuel et al., supra note 89, at 944.
166. Hearing on IRBs, supra note 1, at 4 (statement of Rep. Bart Stupak, Chairman, Comm.
on Energy and Commerce).
167. Id. at 5.
168. Id. One of the IRBs unanimously rejected the protocol. Id.
169. Id.
170. Id.
171. Hearing on IRBs, supra note 1, at 42.
172. Id. at 5 (statement of Rep. Bart Stupak, Chairman, Comm. on Energy and Commerce).
173. Id. at 27 (statement of Gregory Kutz, Managing Director, Government Accountability
Office) (declaring that since federal money was not involved, Coast IRB approval was the only
step necessary before experimentation).
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Coast IRB had reviewed thousands of clinical trials before the sting
operation,174 and it had overseen 300 studies in the month prior to the
investigation.175 Its lax “review” of this product raises questions regarding the
quality of review it gave all of the other studies it had overseen in the past. In
fact, Coast IRB approved all 356 protocols it reviewed in the previous five
years, with only a single dissenting vote.176 That means that only one out of
2,492 votes over five years was a vote to disapprove a study.177 In the
meantime, Coast IRB’s revenue more than doubled from 2004 to 2008 to $9.3
million.178
Moreover, Coast IRB had other conflicts with the FDA prior to this sting
operation. On March 11, 2008, Coast IRB received a warning letter from the
FDA regarding regulatory violations.179 Coast IRB allowed an inexperienced
IRB member, an employee with only a high school education,180 to conduct an
expedited review of a study, which did not qualify for expedited review.181
Coast IRB directed the member to conduct the review despite the full board’s
disapproval of the study’s recruitment advertisement.182 The FDA also cited
Coast IRB for not following its own standard operating procedures.183 As a
result, the FDA suspended Coast IRB’s ability to use expedited review
procedures.184 Just a year later, the FDA issued its death-inducing warning
letter to Coast IRB relating to the sting operation.185 The FDA cited Coast IRB
for multiple failures in not obtaining sufficient information to identify any
reasonably foreseeable risks to subjects.186 As a result, on April 14, 2009,

174. Id. at 15.
175. Barry Meier, Medical Review Firm, After Federal Sting, Goes out of Business, N.Y.
TIMES (Apr. 23, 2009), http://www.nytimes.com/2009/04/23/business/23coast.html.
176. Hearing on IRBs, supra note 1, at 46 (statement of Rep. Edward J. Markey).
177. Id. In contrast, one of the other IRBs contacted by the GAO in this sting operation had
seven votes of disapproval in this study alone. Id. (statement of Rep. Bart Stupak, Chairman,
Comm. on Energy and Commerce).
178. Meier, supra note 175.
179. Letter from Leslie K. Ball, Dir., Food & Drug Admin., to Darren McDaniel, Chief Exec.
Officer, Coast Institutional Review Board (Mar. 11, 2008) (on file with U.S. Dep’t of Health &
Human Servs.), available at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/
2008/ucm1048374.htm [hereinafter Coast Letter 2008].
180. Hearing on IRBs, supra note 1, at 33 (statement of Rep. Donna M. Christensen).
181. Coast Letter 2008, supra note 179.
182. Id.
183. Id.
184. Id.
185. Letter from Deborah M. Autor, Dir., Ctr. for Drug Evaluation & Res., to Daniel Dueber,
Chief Exec. Officer, Coast Institutional Review Board (Apr. 14, 2009) (on file with U.S. Dep’t of
Health & Human Servs.), available at http://www.fda.gov/ICECI/EnforcementActions/Warning
Letters/2009/ucm136673.htm.
186. Id. Failure to determine risks to subjects were minimized under 21 C.F.R. 56.111(a);
failure to determine that risks to subjects were reasonable in relation to anticipated benefits under
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Coast IRB voluntarily agreed to review no new studies as well as not to add
subjects to ongoing studies.187 Only a few days later, Coast IRB closed shop
for good.188
In response to the sting operation, Coast IRB’s Chief Executive Officer
(CEO) lashed out at the government, telling congressional investigators that
they “wasted five weeks of my valuable time” and that it was
“unconscionable” for his government to do this to him.189 Additionally, Coast
IRB did not fire any employees after the incident, not even the IRB chairman
who admitted to not reading the protocol.190 The fact that Coast IRB’s CEO
was more concerned about his company’s reputation than he was about
potential safety breaches in his company makes one wonder where Coast IRB
placed its priorities.191
Fast-forward two years. The same day that HHS released these proposed
regulations, the FDA issued a warning letter to Essex IRB for approving a fake
study192 based on a drug that was withdrawn from the market in 2004 after an
increased risk of heart attacks and strokes.193 Essex IRB approved a trial from
the same made-up sponsor and clinical investigator that was used in the Coast
IRB sting.194 In addition, Essex IRB took a known adverse event out of the
informed consent form without documenting its rationale for the removal.195
Essex IRB could not produce meeting minutes that documented actions taken
by the IRB, and it failed to follow its standard operating procedure.196 As a

21 C.F.R. 56.111(a)(2); failure to make a risk determination; and failure to ensure basic elements
of informed consent in consent form. Id.
187. Id.
188. Coast IRB Folds After FDA Warning, GAO Sting, BIOWORLD TODAY 1, 8 (Apr. 24,
2009).
189. Hearing on IRBs, supra note 1, at 76–77 (statement of Daniel Dueber, CEO, Coast IRB,
LLC).
190. Id. at 81.
191. Id. at 78.
192. Who Watches the Watchmen? 476 NATURE 125 (Aug. 11, 2011). This sting operation
was run by journalists. Id. Essex IRB was considered a major for-profit IRB in 2006. Emanuel et
al., supra note 89, at 943.
193. U.S. DEP’T OF HEALTH & HUMAN SERVS., MAR. 14–21 INSPECTION OF ESSEX
INSTITUTIONAL REVIEW BOARD, INC. (Mar. 21, 2011), available at http://www.circare.org/fda
wls/essexirb_fdafoia_2011-6068.pdf. Essex IRB failed to warn for the potential cardiovascular
risk in the informed consent form. Id.
194. Id.
195. Id.
196. Id. Essex only discovered the fictitious study after the FDA posted an alert regarding a
phony research application. Mari Serebrov, SEC Files Fraud Charges Against Biotech,
Executives, 22 BIOWORLD TODAY 1, 5 (Aug. 4, 2011).
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result, the FDA required Essex IRB to make changes and to submit audits of
ongoing pediatric studies.197
Essex IRB, like Coast IRB, had run into trouble with the FDA in the past.
In 1998, Essex IRB failed to consider local conditions and standards in initial
review and continuing review of studies.198 In response to these citations, the
FDA stopped Essex IRB from approving new studies until the office had
assurance that corrections were made.199 In 2000, Essex IRB failed to conduct
adequate continuing review and failed to fulfill requirements for expedited
review.200 Again, Essex IRB failed to prepare adequate IRB documents.201 The
FDA concluded that Essex IRB’s procedures were inadequate to protect the
rights of research subjects.202
Essex IRB’s response to the latest citations raises questions about its
business’s priorities as well. Essex IRB responded in a letter to the FDA in a
similar manner that Coast IRB’s CEO responded in the congressional
hearings.203 Essex IRB expressed that its IRB was designed to review clinical
research and not to detect fabricated submissions.204
Although an incident as flagrant as making up a company and a drug has
not occurred, research scientists have been convicted or accused of fraudulent
activity, making it important for IRBs to be able to isolate these issues. A
lawsuit filed in September 2011 accused a Duke University researcher of
falsifying medical research.205 In addition, in 2011, two researchers at the Lee

197. Letter from Leslie K. Ball, Dir., Food & Drug Admin., to Nancy Waggoner, Chief Exec.
Officer, Essex Institutional Review Board, Inc. (July 26, 2011) (on file with U.S. Dep’t of Health
& Human Servs.), available at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/
2011/ucm266114.htm.
198. Letter from David A. Lepay, Dir., Ctr. for Drug Evaluation & Res., to William C.
Waggoner, President & Chairman, Essex Institutional Review Board, Inc. (Aug. 27, 1998) (on
file with U.S. Dep’t of Health & Human Servs.), available at http://www.fda.gov/downloads/ICE
CI/EnforcementActions/WarningLetters/1998/UCM066739.pdf.
199. Id.
200. Letter from Steven A. Masiello, Dir., Ctr. for Biologics Evaluation & Res., to Glenn P.
Lambert, Chairman, Essex Institutional Review Board, Inc. (Mar. 01, 2000) (on file with U.S.
Dep’t of Health & Human Servs.), available at http://www.fda.gov/downloads/ICECI/Enforce
mentActions/WarningLetters/2000/UCM068175.pdf.
201. Id. Essex IRB also failed to record the attendance and voting of IRB members. Id.
202. Id.
203. Letter from Glenn P. Lambert, Chairman, Essex Institutional Review Board, Inc., to
Douglas I. Ellsworth, District Dir., Food & Drug Admin. (Apr. 11, 2011) (on file with author),
available at http://www.circare.org/fdawls/essexirb_fdafoia_2011-6068.pdf.
204. Id.
205. Duke University was sued for negligence per se for the IRB’s failure. Complaint at 1,
Aiken v. Duke Univ., No. 11 CVS 4721 (N.C. Super. Ct. Sept. 7, 2011) (alleging that plaintiffs
were exposed to improper and unnecessary chemotherapy due to falsified medical research).
Researcher at the University of Texas MD Anderson Cancer Center issued warnings that the
research was faulty to the researchers and to Duke University from 2006-07. Id. at 10. Nature

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

434

SAINT LOUIS UNIVERSITY PUBLIC LAW REVIEW

[Vol. XXXII:411

Research Institute in Lenexa, Kansas were charged with falsifying study data
in a clinical drug trial.206 Along with the 2011 incidents, 2010 saw multiple
papers retracted from journals after scientific misconduct or data
falsification.207 Doctors have also strayed in research, which has impacted
patient care and the medical market.208 For example, a Massachusetts
anesthesiologist was convicted of health care fraud after falsifying clinical
research about pain management producing six false articles over six years.209
Unfortunately, issues of fraud need to be considered at every step for researchsubjects’ protection. Since IRBs’ primary responsibility is to ensure protection
of subjects, IRB review processes must be robust enough to detect fraudulent
activity.
2. Safety Issues for Research Subjects under Central IRB Mandate
There is not any published evidence that demonstrates how well a central
IRB would work to protect research subjects in all multi-site studies.210
Although there is some IRB efficiency data, IRB efficiency metrics do not
consider IRB quality.211 The NCI is currently working on a pilot study where
the local IRBs at twenty-five sites are responsible for reviewing local context
and the central IRB does not consider local context.212 Why propose

Medicine published in a November 2007 issue the MD Anderson researcher’s notice letter
pointing out errors in the study. Id. at 14. A University of Michigan researcher highlighted the
same issues. Id. at 17.
206. Indictment at 1, United States v. Sharp, No. 5:11-cr-40042-RDR (D. Kan. June 1, 2011).
The researchers allegedly knowingly accepted two subjects that were not qualified for a study due
to age and employment. Id. at 6.
207. On September 24, 2010, more papers, making a total of six papers, were retracted after
scientists were accused of scientific misconduct; in December 2010, the International Anesthesia
Research Society retracted a paper after finding falsified data. Praveen K. Neema, Medical
Research: Is Everything Alright?, 27 J. ANAESTHESIOLOGY CLINICAL PHARMACOLOGY 155,
159–61 (2011).
208. Sentencing Memorandum at 8, United States v. Reuben, No. 10-CR-30002-MAP (D.
Mass. June 22, 2010);
Brendan Borrell, A Medical Madoff: Anesthesiologist Faked Data in 21 Studies, SCI. AM. (Mar.
10, 2009), http://www.scientificamerican.com/article.cfm?id=a-medical-madoff-anesthestesiolo
gist-faked-data. Studies resulted in “the sale of billions of dollars of the potentially dangerous
drugs . . . Celebrex and Vioxx.” Id.
209. Reuben, No. 10-CR-30002-MAP at 3–4. Reuben received a six-month sentence for the
fraud. Neema, supra note 207, at 159.
210. The NCI Central IRB model does not scale well. Memorandum from National Heart,
Lung, and Blood Institute Working Group, Facilitating NHLBI Clinical Trials Through
Optimization of the IRB Process: Are Central IRBs the Solution (June 28–29, 2011) (on file with
author). Without evidence demonstrating appropriate parallels between the NCI and other central
IRBs, studies using the NCI Central IRB are not effective in showing central IRB efficacy.
211. Id.
212. Id. Pilot will be evaluated in late 2012. Id.
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regulations to force multi-site studies to use a central IRB for local review
before finding out the results of this study? The NCI needs to develop metrics
to assess the quality of IRB review before removing additional eyes of
protection.213 There is just not any information out there that shows how often
issues arise related to local context.214 Additionally, current NCI data should
not be used as a model for a mandatory central IRB because NCI parameters
vary from the proposed central IRB regulations in vital aspects. For example,
with the NCI, a majority of institutions still use their own local review for NCI
studies,215 which would be discouraged under the proposed regulations.
Moreover, the NCI central IRB is required to have the expertise to adequately
assess the protocol.216 The proposed regulations have no such requirement for
the central IRB in multi-site studies.217 A central IRB will not function to
protect subjects if it does not have the expertise to adequately assess the
protocol. Therefore, additional studies are necessary from sources that model
the proposed regulations in order to accurately determine that a central IRB
would adequately protect research subjects.
Although there is limited information on the effectiveness of a mandatory
central IRB, it is well known that independent IRBs inherently have conflicts
of interests. The Institute of Medicine defines a conflict of interest as a
circumstance that creates a risk that a primary interest—the promotion of and
protection of research integrity and research-subjects’ welfare—will be
“unduly influenced by a secondary interest,” such as financial interests, pursuit
of professional advancement, and the desire to do favors for others.218
Conflicts of interest place scientific integrity into question, and they jeopardize
public trust in research.219
Independent IRBs have a conflict of interest regardless of whether they are
actually influenced by the secondary interest.220 For-profit IRBs have an

213. Id.
214. Nancy N. Dubler, National Heart, Lung, and Blood Institute Working Group, Central
IRB Considerations: Issues of Ethics and Liability (June 28–29, 2011) (on file with author).
215. Emanuel Proposes U.S. Move to Regional IRB System, 12 GUIDE TO GOOD CLINICAL
PRAC. NEWSL. 12 (2005). See also Winifred A. Meeker-O’Connell, Institutional Review Boards:
Current Compliance Trends and Emerging Models, 9 J. OF HEALTH CARE COMPLIANCE 5, 8–9
(2009) (stating that as of May 2005, only about a quarter of participating sites accepted the CIRB
review).
216. IRB Models: Institutions Consider Central IRB Variations, 12 GUIDE TO GOOD
CLINICAL PRAC. NEWSL. 18 (2004). Oncologists and other health care practitioners are on the
NCI’s Central IRB Board. Meeker-O’Connell, supra note 215, at 8.
217. Human Subjects Research Protections, 76 Fed. Reg. 44,512 (proposed July 26, 2011) (to
be codified at 21 C.F.R. pt. 50, 56).
218. INSTITUTE OF MEDICINE, CONFLICTS OF INTEREST IN MEDICAL RESEARCH,
EDUCATION, AND PRACTICE 6 (2009).
219. Id. at 2.
220. See id. at 47.
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incentive to approve clinical trials: if the IRB does not approve the trial, the
applicants may use a different IRB for the succeeding study.221 Employees are
well aware that rejecting protocols is not good for the company’s bottom
line.222 This long-term relationship between independent IRBs and sponsors
increases the risk that the sponsors influence independent IRB behavior.223
Many question whether for-profit IRBs can “impartially assess industrysponsored research when their revenue comes from the very firms funding the
studies.”224 Although funding for administrative review at an institution may
seem similar to funding a for-profit IRB, the IRB members at the institution
are not paid directly by the sponsors nor does the institution make a profit from
the funding, in contrast to for-profit IRBs.225 Even though local IRBs may have
ulterior motives, such as prestige, to approve trials, money is the “most
powerful incentive to cut corners.”226
In comparison, judges who have financial conflicts of interest are
disqualified from review when there is “clear potential for personal loss” and
when “the financial interest is not too remote.”227 Additionally, physician
interaction with pharmaceutical companies is highly regulated.228 Scrutinizing
financial conflicts of interests is appropriate for IRB review, especially when
the research takes place within a commercial context.229 Uninfluenced IRB

221. Who Watches the Watchmen?, supra note 192.
222. Lemmens & Freedman, supra note 51, at 567.
223. See INSTITUTE OF MEDICINE, supra note 218, at 54.
224. Meeker-O’Connell, supra note 215, at 7.
225. See id.
226. Who Watches the Watchmen?, supra note 192. The cutting of corners could be
subconscious, but there is data that money and bias go hand-in-hand in research. See generally
Katherine Harmon, Industry-Sponsored Drug Trials More Likely to Report Positive Results, SCI.
AM., http://blogs.scientificamerican.com/observations/2010/08/02/industry-sponsored-drug-trialsmore-likely-to-report-positive-results/ (last visited Apr. 19, 2013) (finding that 85 percent of
industry-funded studies reported positive outcomes compared to just 50 percent of governmentfunded studies).
227. Lemmens & Freedman, supra note 51, at 560.
228. See Interactions with Pharmaceutical Industry Representatives, AM. MED. ASS’N,
http://www.ama-assn.org/ama/pub/physician-resources/legal-topics/business-management-topics/
interactions-pharmaceutical-industry-representatives.page (last visited Apr. 19, 2013). For
example, the 2008 Pharmaceutical Research and Manufacturers of American do not allow
pharmaceutical companies to give doctors non-educational items, such as pens. INSTITUTE OF
MEDICINE, supra note 218, at 79. The regulations were created in order to enforce the AMA’s
policy to place the physician-patient relationship ahead of economic self-interest. Ethical
Guidelines for Gifts to Physicians from Industry, AM. MED. ASS’N, http://www.ama-assn.org/
ama/pub/physician-resources/medical-ethics/about-ethics-group/ethics-resource-center/education
al-resources/guidelines-gifts-physicians.page? (last visited Apr. 19, 2013).
229. See Macklin, supra note 23, at 15.
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review improves the likelihood that the IRB is best performing its role in
evaluating risks and potential benefits for research subjects.230
Relationships can also create a separate conflict of interest, in addition to
the financial conflict of interest, for independent IRBs. For example, the
Human Investigation Committee IRB that policed the Fabre Research Clinic
was founded by the same doctor who ran the clinic.231 In 1992, the FDA issued
a warning letter to the Human Investigation Committee IRB, stating that it had
a conflict of interest in reviewing studies at the Fabre clinic.232 This same IRB,
with the same conflict of interest, was overseeing studies at the Fabre clinic
when a volunteer died in 2002.233 In fact, the FDA had inspected the clinic just
six days before the volunteer joined the study.234 It was not until nearly thirteen
years after the FDA first got wind of the conflict of interest issue and after
human protection failures were found in six inspections235 that the FDA finally
shut down the Fabre clinic.236 In addition, Miami-based Southern IRB has
overseen testing at facilities where the husband of the owner of Southern IRB
is a vice president.237 Most recently, on January 21, 2011, the FDA sent Napoli
LLC a warning letter because its study investigator, Doctor Kamrava, also sat
on the IRB that approved his studies.238 These conflicts of interest are unlikely
to go away because a tremendous amount of money is spent on research and
development.239
Both HHS and FDA regulations prohibit an IRB member with a conflict of
interest from participating in the IRB’s review of the study,240 although what
constitutes a conflict of interest is undefined.241 However, the regulations are

230. Id.
231. EVANS ET AL., supra note 97, at 14.
232. Id. at 4.
233. Id.
234. Id.
235. Id.
236. Id. The Human Investigation Committee currently is not registered as an active IRB with
OHRP. Office for Human Research Protections (OHRP) Database for Registered IORGs & IRBs,
Approved FWAs, and Documents Received in the Last 60 Days, U.S. DEP’T OF HEALTH AND
HUMAN SERVS., http://ohrp.cit.nih.gov/search/search.aspx?styp=bsc (last visited Apr. 19, 2013).
237. EVANS ET AL., supra note 97, at 2.
238. Letter from Steven D. Silverman, Dir., Ctr. for Devices and Radiological Health, to
Michael M. Kamrava, Chairman, Napoli LLC (Jan. 21, 2011) (on file with the U.S. Dep’t of
Health and Human Servs.), available at http://www.fda.gov/ICECI/EnforcementActions/Warning
Letters/2011/ucm240960.htm.
239. Ken Gatter, Fixing Cracks: A Discourse Norm to Repair the Crumbling Regulatory
Structure Supporting Clinical Research and Protecting Human Subjects, 73 U. MO. KANSAS
CITY L. REV. 581, 584 (2005).
240. IRB membership, 45 C.F.R. § 46.107(e) (2011); IRB membership, 21 C.F.R. § 56.107(e)
(2011).
241. Icenogle & Dudek, supra note 96, at 65.
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silent as to conflicts of interest the IRB has as an entity. Simple reliance upon
IRB member integrity is not sufficient to address for-profit IRBs’ conflicts of
interest.242
In addition to the conflict of interest issues with independent IRBs, a 2011
study indicates that local IRB members are not fond of central IRBs and that
the majority of medical school IRB members see no reason to use a central
IRB.243 IRB members were concerned that moving review away from the site
of the research study compromises research subjects’ safety because distant
IRBs may not be able to make informed decisions that local IRBs can make.244
After the actual protocol review, the second most important element is that the
reviewers know the researcher’s integrity; local reviewers can have the
“personal understanding, feel, and flavor that’s needed for a heightened level
of review.”245 Local review members are committed to the local community,
and local IRB members do not see for-profit IRBs as having this same
commitment.246 Additionally, these IRB members were concerned that the
quality of central IRB reviews can range considerably.247 It is these concerns
for central IRB quality that create a need for stronger independent IRB
standards.
3. OHRP Regulation of IRBs is Insufficient for Research-Subjects’
Protection
“Anyone who can bring together five people, including a community
representative, a physician, a lawyer, and an ethicist, can set up shop [as an
IRB] and start competing for business.”248 Although IRB registration is
required, the federal government does not endorse with registration that the
registered IRB meets any standards.249 HHS receives three hundred
applications each month to register IRB boards, a fact which congressmen
have suggested indicates that there should be concern about people seeing

242. Lemmens & Freedman, supra note 51, at 558.
243. Robert Klitzman, How Local IRBs View Central IRBs in the U.S., 12 BMC MED. ETHICS
1, 2, 4 (2011). Klitzman conducted two-hour phone interviews with forty-six IRB chairs,
directors, administrators, and members. Id. at 3.
244. Id. at 4, 6. “The farther away you get from the actual group of subjects, the harder it is
for a committee to judge the risk and benefits . . . . An IRB in another state could not make as
informed a decision.” Id. at 6.
245. Id. at 6 (emphasis removed).
246. See id. at 7.
247. Klitzman, supra note 243, at 9, 11.
248. Emanuel et al., supra note 89, at 942.
249. Hearing on IRBs, supra note 1, at 59 (statement of Jerry Menikoff, Dir., Office for
Human Research Protections, Health and Human Services).

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

2013]

IS THE CUSTOMER ALWAYS RIGHT?

439

IRBs as a “quick way to get rich.”250 A group of five people could also create
an IRB in order to easily approve its own studies, instead of being forced to
submit protocols to unaffiliated IRBs.
The same GAO sting operation that caught Coast IRB “rubber-stamping”
approvals also registered a fake IRB online with HHS and solicited research
protocols on its website.251 The GAO’s fake IRB’s CEO was Truper Dawg,252
and the IRB was located in the town of Cheatsville, Arizona.253 HHS registered
this IRB with no questions asked.254 Additionally, the bogus IRB received
research protocols from one company because the research coordinator liked
the IRB’s low price and quick turnaround time.255 This demonstrates that forprofit IRBs are already enticing researchers to select review based on price and
time instead of quality of review. Forcing institutions to use an IRB chosen by
the sponsor, based on price and speed, for review of studies occurring at its
premises places both research subjects and the quality of research at that
institution at risk.
Even with these known risks that for-profit IRBs place on subjects, OHRP
rarely investigates IRBs.256 In fact, in the past, the FDA has inspected just 1
percent of study sites.257 The FDA measures compliance by reviewing records
and consent forms because there currently is no standard to measure the quality
of IRB decisions.258 IRBs are not required to visit or inspect test centers at any
time,259 so central IRBs may be clueless as to the ins and outs of the
institutions with which they are working. Additionally, there are no welldefined standards for continuing review.260 In fact, one IRB member admitted
that his continuing review process was complete after he verified that there

250. Id.; Id. at 1–2 (statement of Rep. Bart Stupak, Chairman, Comm. on Energy and
Commerce). Some of the 300 applications are amendments or renewals. Id. at 59 (statement of
Jerry Menikoff, Dir., Office for Human Research Protections, Health and Human Services).
251. Id. at 5 (statement of Rep. Bart Stupak, Chairman, Comm. on Energy and Commerce).
252. Roy M. Poses, Sham Studies and the Commercial IRBs that Approve Them, and Sham
IRBs and the Government Department that Registers Them, HEALTH CARE RENEWAL (Mar. 31,
2009, 3:07 PM), http://hcrenewal.blogspot.com/2009/03/sham-studies-and-commercial-irbsthat.html.
253. Hearing on IRBs, supra note 1, at 9 (statement of Rep. Greg Walden).
254. Id. at 5 (statement of Rep. Bart Stupak, Chairman, Comm. on Energy and Commerce).
255. Id.
256. Powell, supra note 122, at 1418.
257. Paul Gelsinger & Adil E. Shamoo, Eight Years After Jesse’s Death, Are Human
Research Subjects Any Safer?, 38 HASTINGS CENTER REP. 25, 25 (2008).
258. See Scott Burris & Jen Welsh, Regulatory Paradox: A Review of Enforcement Letters
Issued by the Office of Human Research Protection, 101 NW. U. L. REV. 643, 644 (2007).
259. EVANS ET AL., supra note 97, at 17.
260. See Richard S. Saver, Medical Research Oversight from the Corporate Governance
Perspective: Comparing Institutional Review Boards and Corporate Boards, 46 WM. & MARY L.
REV. 619, 669 (2004).
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were no deaths in the study.261 The current status of IRB regulations are in
trouble and the proposed regulations do nothing to remedy these issues.
The recent sting operations indicate that independent IRBs may threaten
the safety of research subjects by “rubber-stamping” protocol approval.
Without a doubt, however, independent IRBs have a conflict of interest that
increases the risk of harm to research subjects. The current and the proposed
regulations regarding independent IRBs are insufficient to ensure researchsubjects’ safety. Above all, there is no evidence that shows research subjects
will be better protected, or even afforded the same protection given under the
current regulations, by these proposed regulations. Therefore, the proposed
regulations should be amended to place an emphasis on research-subjects’
protection.
III. SUGGESTIONS FOR REGULATIONS IN ORDER TO PRIORITIZE RESEARCHSUBJECTS’ PROTECTION
If forty-four IRBs could not catch a major problem with a study,262 then
fundamental IRB issues need to be addressed before mandating review be
moved to a single IRB. It does not make practical sense to take away additional
eyes of oversight for research-subjects’ protection when IRBs are not
functioning as they ought to function.263 The IRB system needs help because
IRBs appear to have a short-term memory when it comes to adverse
incidents264—IRBs have forgotten incidents, such as Jesse Gelsinger’s death,
all too quickly.265 Fundamental change is necessary in order to give IRBs the
capabilities to adequately monitor multi-site research.266 Suggestions for
change include improving the method by which a sponsor chooses an IRB,
increasing IRB transparency, enforcing IRB turnaround time restrictions,
creating standards for measuring and tracking IRB quality, and developing
avenues of redress for injured research subjects.

261. David Heath & Duff Wilson, System’s Serious Flaws Have Led Many to Call for
Regulatory Reform, SEATTLE TIMES, Mar. 15, 2001, at A11.
262. ARDSNET Case Reverberates with Ethics, Oversight Questions, 11 No.5 GUIDE TO
GOOD CLINICAL PRAC. NEWSL. 1 (2004). The Acute Respiratory Distress Syndrome Network
(ARDSNet) trial was suspended because it exposed patients to inappropriate risks when it
randomized ventilation treatment for critically ill patients. Id. The study was reviewed by fortyfour IRBs at the participating research sites. Id.
263. IRB Seals Fate by Approving Fake Protocol in Federal Sting, IRB ADVISOR, July 1,
2009 (Executive Director of AAHRPP states that a number of IRBs are not functioning at the
level at which they ought to be).
264. See KD ex rel. Dieffenbach v. United States, 715 F. Supp. 2d 587, 598 (D. Del. 2010).
265. In a recent complaint, plaintiffs allege that a gene therapy study failed to mention in an
informed consent form that Gelsinger died in a prior gene therapy experiment. Amended
Complaint at 8, Zeman v. Williams, No. 11-10204-MLW (D. Mass. Apr. 20, 2011).
266. Burris & Welsh, supra note 258, at 682.
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A drastic option would be to follow the precedent of other countries and
either ban for-profit IRBs from reviewing studies or have the government
designate the IRB to review each multi-site study. For example, Switzerland
banned commercial IRBs in response to an incident similar to the Fabre
incident in the United States.267 Swiss officials created new regulations
requiring regulatory approval of IRBs, which resulted in no commercial IRBs
being approved.268 Similarly, a policy in Alberta, Canada requires all research
to be reviewed by designated IRBs,269 which takes the power away from the
sponsor to be able to pick the fastest and cheapest IRB review. Eliminating forprofit IRBs or changing how sponsors could choose an IRB would help reduce
the risk to research subjects by ensuring that sponsors cannot pay their way
into research studies. While banning independent IRBs may not be a popular
option in the United States, there is support for creating non-profit IRBs to
review studies.270 If required to use a central IRB, prominent research
universities and major research sites could band together to place pressure on
sponsors to select non-profit IRBs for multi-site studies.271 Another option
would be to have a national board select the IRB to review each study, similar
to the Canadian policy. The national board could consider IRB expertise and
quality metrics to select the most appropriate IRB for the respective multi-site
study. Although both banning for-profit IRBs and requiring that a national
board select the IRB for each study would require significant changes to the
current regulations, these suggestions would promote the primary purpose of
IRBs in protecting research-subjects’ welfare.
A less radical option would be to propose regulations that increase the
transparency in the IRB process. Regulations need to control who can create a
for-profit IRB, and they need to explicitly discuss conflicts of interest and
interactions with sponsors. The regulations should be written so as to minimize
the circumstances where reasonable individuals would have reason to question
whether professional judgment has been improperly influenced, even if it has
not actually been influenced.272 The regulations should provide research
subjects more information about the IRB process, since the public interest is
best served by encouraging transparency and integrity in research.273

267. Emanuel et al., supra note 89, at 943.
268. Id. The Swiss Supreme Court upheld the new regulations. Id.
269. David Forster, Independent Institutional Review Boards, 32 SETON HALL L. REV. 513,
519 (2002).
270. Macklin, supra note 23, at 19.
271. Id. Research universities and research sites have a vested interest in quality IRB review,
since their reputations are on the line for all research that occurs at their premises. This interest
may be strong enough to initiate action.
272. See INSTITUTE OF MEDICINE., supra 218, at 49. However, disclosure alone does not
eliminate conflicts of interest. Id. at 29.
273. Konrady v. Oesterling, 149 F.R.D. 592, 597 (D. Minn. 1993).
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Transparency would be improved if the consent form disclosed to research
subjects the IRB name, the IRB’s profit or non-profit status, and the changes, if
any, that the IRB made to the protocol before approval. Research subjects, as
well as the research sites, will be better able to assess the risk of undue
influence on the IRB’s judgment if they are given sufficient information
regarding the nature, scope, duration, and monetary value of the IRB’s
relationship with the study sponsor.274
This transparency will help improve volunteer trust in medical research.275
Research subjects currently have no assurances that an IRB places their
welfare as its highest priority, since these for-profit companies can hide behind
the walls of secrecy.276 All states should enact a law, following Maryland’s
lead, requiring IRBs to make all meeting minutes available to the public. This
disclosure and improved transparency could provide incentives for sponsors to
choose reputable IRBs.
Regulations should also set review time minimums so that independent
IRBs can no longer advertise or compete on the speed of review. Since recent
IRB failures have been linked to IRB time constraints,277 time-pressured
reviews should be avoided whenever possible. The regulations need to set
minimum turnaround times for IRB review, which would help ensure that
independent IRBs are not squeezing the reviews into short turnaround times in
order to compete for business.278 Forty-eight hour guarantees, like the one the
Essex IRB promises on its website,279 should not be allowed. Reducing the
ability for independent IRBs to compete on review time will improve researchsubjects’ protection.
In addition, HHS should create standards by which to evaluate IRB quality,
and then the agencies should rely on this quality data before creating new
regulations. Simply relying on public comment does not provide the same kind
of support as factual data, especially when considering that the lives and wellbeing of research subjects are at stake. The agencies could require independent
274. See INSTITUTE OF MEDICINE, supra 218, at 67. Although some studies have found that
research participants’ decisions to participate in studies are not affected by the investigator’s
financial relationships, these studies did not fully explain the risks of conflicts of interests to the
research subjects. Id. at 78. In addition, research subjects may feel differently about the IRB being
financially supported by the study sponsors than they do about investigators, given the IRB’s
primary purpose is to protect research subjects.
275. See Lemmens & Freedman, supra note 51, at 577.
276. See supra text accompanying note 132.
277. Saver, supra note 260, at 660. IRBs may spend two to eight minutes on average on a
given protocol. Id. at 659.
278. The president of one of America’s largest independent IRBs says that it advertises speed
and efficiency to research sponsors. Lemmens & Freedman, supra note 51, at 551.
279. Sponsors will be notified of action within forty-eight hours of Board review. Full Board
Review, ESSEX INSTITUTIONAL REVIEW BOARD, INC., http://www.essexirb.com/submissions/full
board.htm (last visited Apr. 19, 2013).
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IRBs to be accredited through institutions like the Association for the
Accreditation of Human Research Protections Programs (AAHRPP).280
However, since none of the accreditation standards are revolutionary, it is
unknown whether accreditation will solve the issues with IRBs.281 Before
mandating a central IRB, HHS should review data from the NCI and other
recent recommendations. For example, in September 2011, President Obama
ordered the Presidential Commission for the Study of Bioethical issues to
review research-subjects’ protection.282 Additionally, the Secretary’s Advisory
Committee on Human Research Protections recommended that a single federal
agency review all research, regardless of whether it involves federal funding or
is an FDA-regulated product, and that uniform standards for managing
conflicts of interests be created.283 Research subjects will be better protected
with a research protocol overhaul rather than the quick-fix “protections” these
proposed regulations provide.
Regulations focusing on improving IRBs are vital to the protection of
research subjects; however, legal remedies for injured research subjects should
also be addressed in the new regulations. The current regulations provide no
legal remedies or redress for research-subjects’ injuries.284 While institutions
or IRBs may be able to require study sponsors to indemnify them for
negligence in research studies,285 research subjects do not have a similar
redress for their injuries. Research subjects, as a practical matter, are unable to
contract with the study sponsors for help when something goes awry in a
study.286 IRBs should be held legally responsible when they play a role in a

280. See ASSOCIATION FOR THE ACCREDITATION OF HUMAN RESEARCH PROTECTION
PROGRAMS, INC., http://www.aahrpp.org/ (last visited Apr. 19, 2013). The other accrediting
company, the Partnership For Human Research Protection (PHRP) dissolved in 2005. PHRP
Accreditation Group Dissolves, THOMPSON (Sept. 8, 2005), http://www.thompson.com/public/
printpage.jsp?id=1122&pageid=newsbrief. Essex IRB was accredited by PHRP. Partnership for
Human Research Protection (PHRP) Accreditation, ESSEX INSTITUTIONAL REVIEW BOARD,
INC., http://www.essexirb.com/about/phrp.htm (last visited Apr. 19, 2013).
281. Icenogle & Dudek, supra note 96, at 67. Critics argue that accreditation adds another
layer of regulation “to an already heavily regulated environment.” Beasley, supra note 114, at 61.
282. SACHRP Urges Simplified Federal Trial Oversight, 18 No.12 GUIDE TO GOOD
CLINICAL PRAC. NEWSL. 15 (2011).
283. Id.
284. See Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512–31 (proposed
July 26, 2011) (to be codified at 21 C.F.R. pt. 50, 56).
285. See Lis & Murray, supra note 66, at 118–20. Essex IRB requires sponsors to sign an
indemnification agreement to release Essex IRB from ordinary negligence. Indemnification
Agreement, ESSEX INSTITUTIONAL REVIEW BOARD, available at http://www.essexirb.com/forms/
indemnification.htm (last visited Apr. 19, 2013).
286. Michelle M. Mello & Steven Joffe, Compact versus Contract – Industry Sponsors’
Obligations to Their Research Subjects, 356 NEW ENG. J. MED. 2737, 2739–40 (2007).
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subject’s injury.287 The public health is not served when IRBs, especially forprofit IRBs, can escape the consequences of misconduct.288 Research studies
advance public health by improving options for treatment of diseases, but there
can be no scientific progress in clinical trials without volunteer subjects. The
public health benefits when volunteers trust the research system. However,
volunteer subjects will lose confidence in the system if for-profit IRBs cannot
be held liable for decisions that cause injuries. A benefit of turning to the legal
system is that it adds no bureaucracy to the regulated environment.289 If HHS
wants to outsource ethical reviews to for-profit companies, research subjects
should be provided an easier way to be compensated from the IRBs that fail to
protect them.
Proposed regulations simply cannot rely on just the goodwill of IRB
members—research subjects require more than goodwill to be protected from
the risks of clinical trials.290 Quality IRB reviews depend on an effective
protocol process review,291 and new proposed regulations are necessary in
order to effectively protect research subjects.
CONCLUSION
HHS designed IRBs for the primary purpose of protecting human subjects
volunteering in research studies.292 These volunteers put their lives at risk in
clinical trials, which may be of no benefit to them.293 At a minimum, the public
owes these volunteers the dignity of having someone look out for their best
interests. Regulations that will push more research review into the hands of
for-profit IRBs without any additional oversight does not give these research
subjects the protection they deserve. Central IRBs might be the solution for
multi-site trials, but only with additional regulations that adequately protect
research subjects, not with the present regulations that serve research integrity
interests rather than individual safety interests.
When one out of three IRBs tested in a sting operation was found to have
“rubber-stamped” a protocol’s approval,294 it raises concerns about all other
IRBs. Catching Essex IRB in a similar sting two years later demands action
from HHS. IRB reform is necessary to improve the protection of research
subjects. If HHS wants to mandate the use of central IRBs, at a minimum the
287. Hoffman & Berg, supra note 106, at 411.
288. See id. at 406–11.
289. Beasley, supra note 114, at 61.
290. Lemmens & Freedman, supra note 51, at 575.
291. Carl H. Coleman, Rationalizing Risk Assessment in Human Subject Research, 46 ARIZ.
L. REV. 1, 13 (2004).
292. See supra text accompanying note 9.
293. Hoffman, supra note 92, at 738.
294. Hearing on IRBs, supra note 1, at 2 (statement of Rep. Bart Stupak, Chairman, Comm.
on Energy and Commerce).
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regulations should provide standards for measuring IRB quality, increased
transparency, stronger regulation of independent IRBs, and an avenue of
redress for injured subjects. There is injustice in leaving research subjects
without redress when the companies profiting from their protocol review fail to
protect them.
Protecting research subjects does not require that research efforts take a
backseat to the research-subjects’ interests, it simply requires that the research
subjects’ safety be placed ahead of financial interests.295
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